R&D Focus On Improving Existing Biopharmaceutical Molecules Drives the Market for Biobetters, According to a New Trend Report Published by Global Industry Analysts, Inc.

GIA announces the release of a trend report on Biobetters. Market for Biobetters is projected to witness strong growth led by increasing R&D investments in improving the therapeutic performance of existing and known biological molecules.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Biobetters: A Trend Report

San Jose, California (PRWEB) January 24, 2014

Follow us on LinkedIn – Biobetters or biosuperiors are novel molecules derived from successful, approved biologic products customized to enhance its overall efficacy. Biobetters are developed to offer superior characteristics over the originator biological molecule in terms of extended half-life in human body, improved bioavailability, lower immunogenicity, higher purity, and fewer side-effects.
As an improved version of the original drug, biobetters offer significant clinical and market advantages for biopharmaceutical companies thus encouraging R&D investments in this space. As innovative and affordable biologics capable of enhancing quality of care at lower costs, government support and funding is also on the rise. Given their ability to lower drug costs, expand access to drugs, infuse competition and accelerate biomedical innovation, biobetters are poised to witness strong growth in the coming years. A key challenge however is the lack of clear regulatory guidelines that make it difficult for manufacturers to receive marketing approval for biosuperiors.

The trend report titled “Biobetters” announced by Global Industry Analysts Inc., is a focused research paper which provides cursory insights into the product, future prospects, and corporate initiatives of key companies worldwide. Also covered are companies such as Amgen Inc., Cantab Biopharmaceuticals Ltd., Crucell NV, GreenCross Corporation, Hanmi Pharm Co. Ltd., Medgenics Inc., PharmaEssentia Corporation, Polytherics Ltd., SynBio LLC, Teva Pharmaceutical Industries Ltd., and Xencor Inc., among others.

For more details about this trend report, please visit http://www.strategyr.com/TrendReport.asp?code=146053.

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/


Contact

Attachments